Acorda announces data of GGF2 preclinical studies for focal ischemic stroke Acorda Therapeutics.

These data display that GGF2 could be administered successfully in preclinical models of stroke up to a week following event. Acorda is definitely conducting preclinical stroke research with GGF2 further, and if the info continue to show guarantee, we plan to advance the substance to human medical trials in stroke, as well as the presently planed trials in center failure. Acorda programs to initiate Phase 1 studies in individuals with heart failure based on an Investigational New Medication application filed with the U.S. Food and Medication Administration in March 2010. The company can be pursuing preclinical studies in other cardiac and neurological applications for GGF2 and other neuregulin growth factors.. Acorda announces data of GGF2 preclinical studies for focal ischemic stroke Acorda Therapeutics, Inc, today announced that data from preclinical studies show that Glial Development Factor 2 promoted functional recovery following a permanent focal ischemic stroke.Researchers pointed out that Medicare hospital and spending costs were comparable. The study was published Sept. 22 in the journal JAMA. A randomized trial may be warranted to assess whether more liberal ICU admission policies improve mortality for sufferers with pneumonia, the study authors wrote. The study only found a link, than a cause-and-effect relationship rather, between ICU admission rates and survival. The findings argue against efforts to reduce ICU admissions, at least for older patients with pneumonia, Dr. Ian Barbash and Dr.

-->